Biocon Limited has announced its financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of 10% (Re. 0.50 per share) for FY26. Furthermore, the company detailed a major strategic move to integrate Biocon Biologics Limited as a wholly-owned subsidiary. The Board also approved significant leadership appointments, a new long-term incentive plan, and the appointment of new statutory auditors for the next five years.
Financial Performance Overview
For the financial year ended March 31, 2026, Biocon reported standalone revenue of Rs. 23,464 million. On a consolidated basis, the company delivered a robust performance with total income reaching Rs. 1,72,695 million, highlighting significant growth in its biosimilars and CRDMO segments. The board has recommended a final dividend of Re. 0.50 per share, with the record date set for July 3, 2026.
Integration of Biocon Biologics
In a major corporate consolidation, Biocon is acquiring the remaining ~2% stake in its material subsidiary, Biocon Biologics Limited (BBL), to make it a wholly-owned subsidiary. This integration is designed to simplify the corporate structure, enable a unified capital allocation strategy, and drive operational synergies, including a complementary portfolio of Biosimilars and GLP-1s.
Governance and Leadership Changes
The company announced a transition in its auditing partners, recommending M/s. S. R. Batliboi & Associates LLP as statutory auditors for a five-year term, replacing M/s. B S R & Co. LLP. Additionally, the company strengthened its leadership team by designating Dr. Anuj Goel as Chief Development Officer and Mr. Susheel Umesh as Chief Commercial Officer – Emerging Markets as Senior Management Personnel.
Strategic Board Appointments
To support its global biopharmaceutical leadership goals, the company has announced the appointment of several new independent directors, including Mr. Rajiv Malik, Mr. Daniel Bradbury, Mr. Peter Baron Piot, Mr. Arun Suresh Chandavarkar, and Ms. Nivruti Rai. Mr. Thomas Jason Roberts will join as a Non-Executive Non-Independent Director, with all appointments effective August 1, 2026.
Employee Incentives and Upcoming AGM
The Board also approved the Biocon Unity Long Term Incentive Plan 2026, aimed at aligning employee interests with long-term company growth through various equity-based incentives. The 48th Annual General Meeting is scheduled for August 6, 2026, and will be conducted through virtual means.
Source: BSE
